Las Vegas, NV -- (SBWIRE) -- 12/16/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Coronado Biosciences Inc (NASDAQ:CNDO), Kandi Technologies Group Inc (NASDAQ:KNDI),Elephant Talk Communications Corp (NYSEMKT:ETAK), rca Biopharma Inc (NASDAQ:ABIO)
Coronado Biosciences Inc (NASDAQ:CNDO) managed to keep its gain at 20.79% on above-normal volume of 19.27M shares. The stock settled at $2.15 after floating in a range of $2.06 to $2.78. Its latest price has reached market capitalization of $72.98 milion. Its 52-week range has been $1.25 to $12.70. Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include TSO or CNDO-201, which is a biologic comprising Trichuris suis ovathe, the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn?s disease, ulcerative colitis, multiple sclerosis, autism.
For How Long CNDO will fight for Profitability? Read This Trend Analysis report
Kandi Technologies Group Inc (NASDAQ:KNDI) traded up on a volume of 1.49 million, higher than its standard daily volume. Shares have gained 7.02% to $7.77. Over the last twelve months, the stock has gained 115.82% and faced a worst price of $3.37. Kandi Technologies Group, Inc., through its subsidiaries, engages in the design, development, manufacture, and commercialization of various vehicles. It offers electrical vehicles, all-terrain vehicles, go-karts, and specialized automobiles; and utility vehicles, three-wheeled motorcycle, refitted cars, super-mini-cars, and various auto generators. Kandi Technologies Group, Inc. sells its products through trading companies in North America, Europe, and China.
For How Long KNDI’s Gloss will Attract Investors? Find out via this report
Elephant Talk Communications Corp (NYSEMKT:ETAK) settled 6.61% higher at $1.29 on above-normal volume of 900,331.00 shares during the last trading day. The stock has its 12-month high at $1.68 and 52-week low price was $0.53. It traded in a range of $1.25 to $1.40 during the last trading day. Elephant talk Communications Corporation operates as mobile software defined network architecture vendor in Europe, the Middle East, Africa, and the Americas. It primarily provides mobile, fixed, and convergent telecommunications software services to the telecommunications and financial industries.
Why Should Investors Buy ETAK After the Recent Fall? Just Go Here and Find Out
In the last trading session, Arca Biopharma Inc (NASDAQ:ABIO) was up on low volume, trading at a volume of 368,750.00 versus its average daily volume of 1.62 million shares. At $1.52, the stock has attained market capitalization of 23.83 million. ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Broomfield, Colorado.
Will ABIO Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)